TABLE 3.

Prior exposure to antifungal therapy for patients with non-wild-type Trichophyton isolates

Case ID	Antifungal(s) to which patient was exposeda		Time of first terbinafine exposure (yr)b		No. of treatment courses with terbinafine (wks of treatment)
	Topical	Systemic	Topical	Systemic	Topical	Systemic
1	Terbinafine	Terbinafine	NA	2017	0 (0)	1 (NA)
2	None	Terbinafine	—	2014	0	1 (2)
3	Terbinafine, amorolfine, ketoconazole	Terbinafine, itraconazole	NA	2013	6c (8)	2 (24)
4	Terbinafine, amorolfine, ciclopirox	Terbinafine, itraconazole, fluconazole	2004	2010	3 (7)	3 (53)
5	Terbinafine, ketoconazole	Terbinafine, itraconazole	2010	2015	9c (20)	2 (6)
6	Terbinafine	Terbinafine, itraconazole	2014	2015	3 (8)	2 (17)
7	Amorolfine	Terbinafine, fluconazole, itraconazole, griseofulvin	NA	2000	NA (NA)	3 (36)
8	Terbinafine, amorolfine, ketoconazole	Terbinafine, itraconazole	2012	2005	2 (24)	3 (28)
9	None	Terbinafine, itraconazole	—	2015	0 (0)	1 (NA)
10	NA	Terbinafine, itraconazole	NA	Before 1990	NA (NA)	NA (>104)
11	Terbinafine, miconazole-hydrocortisone combination	Terbinafine, itraconazole	2017	2017	2 (10)	3 (28)
12	Terbinafine, amorolfine, ketoconazole	Terbinafine, itraconazole, griseofulvin	2009	2008	NA (NA)	2 (24)
13	Terbinafine	Terbinafine	2010	2014	NA (NAd )	NA (NA)
14	Terbinafine	Terbinafine, itraconazole	2018	2018	1 (16)	1

^aNA, not available.

^b—, no first-exposure year, since topical terbinafine was not used.

^cTwo of the treatment courses consisted of one application only of terbinafine hydrochloride.

^dSeveral treatment courses (2 to 4 weeks) in a 2-year period.